SCHEMBL4045003

SCHEMBL4045003

CN(C)c1cccc(C2(C(C(=O)NC3CCCCC3)C3CCCCC3)Nc3ccc(F)cc3N2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GFER P55789 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HTT P42858 1/20 0.42
IDH1 O75874 6/20 0.38
CYP2C19 P33261 1/20 0.38
OPRL1 P41146 1/20 0.38
POLB P06746 2/20 0.38
NR1H4 Q96RI1 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR2B P41595 1/20 0.37
PKM P14618 1/20 0.37
BACE1 P56817 1/20 0.37
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038970 0.92 NPC1 (0.48) NPC1RAB9ASMN1; SMN2KDM4EGFER
SCHEMBL4034657 0.91 SMN1; SMN2 (0.50) NPC1RAB9ASMN1; SMN2KDM4EGFER
SCHEMBL4038973 0.83 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HTTIDH1
SCHEMBL4036972 0.81 NPC1 (0.41) NPC1RAB9ASMN1; SMN2CYP2C19POLB
SCHEMBL4036796 0.81 NPC1 (0.41) NPC1RAB9ASMN1; SMN2CYP2C19POLB
SCHEMBL4034659 0.80 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL4040710 0.79 NPC1 (0.42) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL4041164 0.79 NPC1 (0.42) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL4037171 0.78 NPC1 (0.47) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL4035697 0.77 CNR1 (0.43) NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed